- Home
- ZLAB vs KYMR Comparison
ZLAB vs KYMR Comparison
Compare ZLAB & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- KYMR
- Stock Information
- Founded
- ZLAB 2013
- KYMR 2015
- Country
- ZLAB China
- KYMR United States
- Employees
- ZLAB N/A
- KYMR N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- ZLAB Health Care
- KYMR Health Care
- Exchange
- ZLAB Nasdaq
- KYMR Nasdaq
- Market Cap
- ZLAB 3.0B
- KYMR 2.6B
- IPO Year
- ZLAB 2017
- KYMR 2020
- Fundamental
- Price
- ZLAB $26.05
- KYMR $40.61
- Analyst Decision
- ZLAB Strong Buy
- KYMR Buy
- Analyst Count
- ZLAB 3
- KYMR 15
- Target Price
- ZLAB $55.00
- KYMR $55.60
- AVG Volume (30 Days)
- ZLAB 482.4K
- KYMR 532.1K
- Earning Date
- ZLAB 02-25-2025
- KYMR 02-20-2025
- Dividend Yield
- ZLAB N/A
- KYMR N/A
- EPS Growth
- ZLAB N/A
- KYMR N/A
- EPS
- ZLAB N/A
- KYMR N/A
- Revenue
- ZLAB $355,748,000.00
- KYMR $87,563,000.00
- Revenue This Year
- ZLAB $49.04
- KYMR N/A
- Revenue Next Year
- ZLAB $46.70
- KYMR $33.16
- P/E Ratio
- ZLAB N/A
- KYMR N/A
- Revenue Growth
- ZLAB 35.01
- KYMR 86.92
- 52 Week Low
- ZLAB $13.48
- KYMR $26.92
- 52 Week High
- ZLAB $36.60
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- ZLAB 50.14
- KYMR 47.90
- Support Level
- ZLAB $23.82
- KYMR $40.20
- Resistance Level
- ZLAB $25.64
- KYMR $44.34
- Average True Range (ATR)
- ZLAB 1.24
- KYMR 2.58
- MACD
- ZLAB 0.06
- KYMR 0.29
- Stochastic Oscillator
- ZLAB 64.45
- KYMR 57.47
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.